Novel co-crystal of enavogliflozin

MYPI2025001896A0Undetermined Publication Date: 2024-03-28DAEWOONG PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001896
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-28
Filing Date
2023-09-27
Publication Date
2024-03-28

AI Technical Summary

Technical Problem

The existing polymorphs of inavogliflozin have low solubility, which affects its bioavailability and stability, making it challenging for effective pharmaceutical formulation and administration, particularly for high-dose treatments.

Method used

A novel co-crystal form of inavogliflozin with proline (inavogliflozin/proline co-crystal) is developed, which enhances solubility and stability through hydrogen bonding, improving water solubility and oral absorption by forming a 1:1 ratio with proline, characterized by specific X-ray diffraction and DSC patterns.

Benefits of technology

The inavogliflozin/proline co-crystal demonstrates increased solubility in artificial gastric and intestinal fluids, improved oral absorption, and prolonged drug effect with enhanced stability and bioavailability, suitable for high-dose administration and prolonged therapeutic action.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025001896_DRAWING_001
    Figure PI2025001896_DRAWING_001
  • Figure PI2025001896_DRAWING_002
    Figure PI2025001896_DRAWING_002
  • Figure PI2025001896_DRAWING_003
    Figure PI2025001896_DRAWING_003
Patent Text Reader

Abstract

The present invention relates to a co-crystal of enavogliflozin. The enavogliflozin co-crystal of the present invention enhances the solubility of enavogliflozin in artificial gastric fluid and artificial intestinal fluid. This improved solubility of enavogliflozin may be particularly advantageous for the development of oral formulations for indications requiring high-dose administration. The enavogliflozin co-crystal also exhibits stability equivalent to that of existing crystalline forms of enavogliflozin, making it highly valuable as an active pharmaceutical ingredient of enavogliflozin. Furthermore, the co-crystal of the present invention has a longer half-life and higher in vivo exposure (AUCinf) compared to the existing crystalline form A, resulting in prolonged efficacy, and thus can be usefully employed in the development of various indications and / or formulations requiring such properties. FIGURE 3
Need to check novelty before this filing date? Find Prior Art

Description

Novel co-crystal of inabogliflozin

[0001] The present invention relates to a co-crystal of inabogliflozin.

[0002] The selection of a desirable solid form of an active ingredient, such as a pharmaceutically acceptable salt form, co-crystal, polymorph, or pseudo-polymorph, has a very important impact on the development of the raw drug manufacturing process and the design and formulation of the finished drug product.

[0003] Specifically, the salts, cocrystals, polymorphs, and pseudopolymorphs of a raw pharmaceutical ingredient affect the final stages of its manufacturing, namely, recrystallization and purification, which affect the recrystallization yield, process speed, and purity. Crystal size and shape can affect the crystallization rate, which in turn affects productivity and manufacturing costs.

[0004] In addition, from a pharmaceutical perspective, physicochemical properties such as hygroscopicity, stability, solubility, particle flowability, and dissolution rate are affected by salts, co-crystals, polymorphisms, and pseudo-polymorphisms, and thus become factors that determine the production process, production and storage conditions, and shelf life of finished pharmaceutical products.

[0005] Meanwhile, when the bioavailability of a drug is affected by the physicochemical properties of the raw drug product, more care is required in selecting salts, co-crystals, polymorphs, and pseudo-polymorphs. Therefore, optimized salts, co-crystals, polymorphs, and pseudo-polymorphs are very important in terms of technology development and approval.

[0006] The purpose of the present invention is to explore a novel co-crystal of inabogliflozin, analyze its physicochemical characteristics, develop a co-crystal capable of maximizing pharmacological activity, and improve the low solubility, which is a shortcoming of the existing polymorphic crystal.

[0007] SGLT-2 (sodium glucose cotransporter 2) is a transporter that, along with SGLT-1 (sodium glucose cotransporter 1), is responsible for excessive blood sugar reabsorption in the kidneys, with SGLT-2 playing a major role. Therefore, when SGLT-2 inhibitors inhibit the SGLT-2 transporter, the amount of blood sugar excreted in the urine increases, which ultimately lowers blood sugar and further excretes the calories contained in blood sugar, resulting in weight loss.

[0008] One of the drugs developed as an SGLT-2 inhibitor that can be usefully used as a treatment for type 2 diabetes due to such effects is Enavogliflozin, represented by the structural formula (chemical formula 1) below, and disclosed in Korean Patent Publication No. 2014-0022086 (Patent Document 1).

[0009] [Chemical Formula 1]

[0010]

[0011] In addition, Republic of Korea Patent Publication No. 2017-0142904 (Patent Document 2) discloses a crystalline form of inabogliflozin and a manufacturing method for manufacturing the crystalline form of inabogliflozin.

[0012] However, the crystalline form of inabogliflozin disclosed in Korean Patent Publication No. 2017-0142904 (Patent Document 2) has a disadvantage in that its solubility is only 0.25 mg / mL.

[0013] Accordingly, the inventors of the present invention conducted research on a co-crystal capable of improving the solubility of inabogliflozin, and as a result, confirmed that when manufactured in a specific co-crystal form, stability is excellent while solubility is improved, thereby completing the present invention.

[0014] [Prior Art Literature]

[0015] [Patent Document]

[0016] Patent Document 1. Republic of Korea Patent Publication No. 2014-0022086

[0017] Patent Document 2. Republic of Korea Patent Publication No. 2017-0142904

[0018] The present invention provides a novel cocrystal of inavogliflozin with excellent stability and solubility, and a method for preparing the same. The present invention also provides a pharmaceutical composition comprising the novel cocrystal of inavogliflozin as an active ingredient.

[0019] The present invention provides a novel co-crystal of inabogliflozin represented by the following structural formula (chemical formula 2) and a method for producing the same.

[0020] [Chemical Formula 2]

[0021]

[0022] In order to overcome the low solubility of inabogliflozin, the inventors of the present invention attempted to design a co-crystal by selecting amino acids and organic acids with very high solubility and rich in NH, N, O, and OH.

[0023] The amino acids and organic acids selected for co-crystal production are aspartic acid, acetylsalicylic acid, citric acid, nicotinic acid, nicotinamide, beta-cyclodextrin, propylene glycol, phenylalanine, lactose monohydrate, L-proline, urea, L-lysine, L-pyroglutamic acid, orotic acid monohydrate, maleic acid, malic acid, L-ascorbic acid, fumaric acid, succinic acid, malonic acid, oxalic acid trihydrate, L-tartrate, sodium chloride, L-serine, L-arginine, L-valine, L-methionine, threonine, glycine, L-alanine, L-cysteine, L-tryptophan, L-asparagine, L-isoleucine, L-glutamine, L-histidine, and L-glutamic acid.

[0024] An attempt was made to manufacture co-crystals of inavogliflozin using the 38 amino acids and organic acids above, and three co-crystals were obtained: inavogliflozin / proline co-crystal, inavogliflozin / methionine co-crystal, and inavogliflozin / proline hydrate.

[0025] As a result of evaluating the solubility of inavogliflozin / proline cocrystal, inavogliflozin / methionine cocrystal, and inavogliflozin / proline hydrate cocrystal in pH 1.2 and pH 6.8 eluates, it was confirmed that the three cocrystals, inavogliflozin / proline cocrystal, inavogliflozin / methionine cocrystal, and inavogliflozin / proline hydrate, had higher solubility up to the initial 2 hours than the inavogliflozin crystal form, indicating that the initial solubility was improved through the cocrystals.

[0026] However, the inavogliflozin / proline hydrate cocrystal had a problem of low cocrystal manufacturing reproducibility during scale-up, and the inavogliflozin / methionine cocrystal was expected to have low stability due to its low melting point of 106℃. In fact, as a result of a 4-week harsh stability test at 60℃, the purity of the inavogliflozin / methionine cocrystal decreased by approximately 3% in just 4 weeks, confirming that it was less stable than the inavogliflozin crystal form and the inavogliflozin / proline cocrystal. Through this, it was confirmed that the inavogliflozin / proline cocrystal had the best stability and solubility.

[0027] Through experimental optimization, a method for reproducibly manufacturing inavogliflozin / proline cocrystals was established, and the inavogliflozin / proline cocrystals manufactured in this way showed approximately 21% increased solubility in artificial gastric fluid and approximately twice the solubility in artificial intestinal fluid compared to the existing inavogliflozin crystal form, and also showed improved initial solubility. In addition, due to the above-mentioned solubility characteristics, improved effects were confirmed in oral absorption effects and actual mouse pharmacokinetic experiments.

[0028] Therefore, using the inavogliflozin / proline cocrystal of the present invention, it is possible to manufacture an oral formulation with improved solubility of inavogliflozin. Improved solubility of inavogliflozin may be advantageous in the development of oral formulations for indications requiring high-dose administration.

[0029] Inabogliflozin / proline cocrystal is formed by hydrogen bonding of one molecule of inabogliflozin and one molecule of proline (L-proline) in a 1:1 ratio.

[0030] Since proline, which has high water solubility, forms a cocrystal with inavogliflozin through hydrogen bonding, inavogliflozin also dissolves in water when proline dissolves due to the interaction with proline, so that water solubility and solubility in artificial gastric fluid and artificial intestinal fluid increase.

[0031] The inabogliflozin / proline cocrystal of the present invention is a novel solid form of inabogliflozin that has not been reported anywhere else.

[0032] In one specific embodiment of the present invention, an inabogliflozin / proline co-crystal is provided, characterized by an X-ray powder diffraction pattern having four or more, for example, four, five, six, seven, eight or more, diffraction peaks at 2[θ] values ​​selected from 4.72±0.2, 6.81±0.2, 7.93±0.2, 8.59±0.2, 14.75±0.2, 15.21±0.2, 17.23±0.2, 18.80±0.2, 21.19±0.2, 24.42±0.2, and 27.29±0.2 in X-ray diffraction (PXRD) analysis.

[0033] In particular, the X-ray powder diffraction pattern is characterized by having diffraction peaks at 2[θ] values ​​selected from 6.81±0.2, 8.59±0.2, 14.75±0.2, 17.23±0.2, and 18.80±0.2.

[0034] More specifically, the inabogliflozin / proline cocrystal is characterized by an X-ray powder rotation pattern whose peak positions are consistent with the peak positions listed in Table 1 below.

[0035] 2θ(±0.2°)d (Å)I / I o(%)4.7218.733.36.8113.0100.07.9311.147.08.5910.363.114.756.081.615.215.831.017.235.150.918.804.763.221.194.222.524.423.628.327.293.325.4

[0036] In another specific example of the present invention, the inavogliflozin / proline cocrystal is characterized by showing an endothermic peak with an endothermic onset temperature of 217.71°C±3°C and an endothermic temperature of 219.42°C±3°C in differential scanning calorimetry (DSC) analysis. The inavogliflozin / proline cocrystal according to the present invention is in a form in which 1 equivalent of inavogliflozin is combined with 1 equivalent of proline. According to nuclear magnetic resonance spectroscopy (NMR) analysis, it can be confirmed in the H-NMR spectrum that the inavogliflozin / proline cocrystal is composed of 1 molecule of inavogliflozin and 1 molecule of proline.

[0037]

[0038] Another specific embodiment of the present invention provides a method for preparing the above inabogliflozin / proline co-crystal.

[0039] Although not limited thereto, the inabogliflozin / proline cocrystal is prepared by a process including the steps of (a) mixing inabogliflozin and an organic solvent and adding proline thereto; (b) stirring the resultant of step (a); and (c) vacuum-drying the resultant of step (b) to obtain the inabogliflozin cocrystal.

[0040] The method of the present invention for producing an inabogliflozin / proline co-crystal is described in detail step by step as follows.

[0041]

[0042] (a) Mixing of inabogliflozin and organic solvent and addition of proline

[0043] First, the method of the present invention includes a step of mixing solid inavogliflozin and an organic solvent and adding proline thereto. The physicochemical form of the solid inavogliflozin used herein is not particularly limited. For example, the solid inavogliflozin may be inavogliflozin crystalline form A, crystalline form B, crystalline form C, crystalline form D, or inavogliflozin amorphous form, which are reported to have the following X-ray diffraction spectrum through Experimental Example 4 of Korean Patent Publication No. 2017-0142904.

[0044] Crystalline Form A: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 6.2°±0.2°, 7.2°±0.2°, 8.8°±0.2°, 17.6°±0.2°, 19.0°±0.2°, 22.5°±0.2°, and 25.1°±0.2°.

[0045] Crystalline Form B: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 7.0°±0.2°, 14.9°±0.2°, 17.7°±0.2°, 18.8°±0.2°, 20.6°±0.2°, 21.8°±0.2°, and 23.5°±0.2°.

[0046] Crystalline Form C: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ values ​​selected from 5.6°±0.2°, 7.3°±0.2°, 15.7°±0.2°, 17.2°±0.2°, 18.9°±0.2°, 21.2°±0.2°, and 21.9°±0.2°

[0047] Crystalline Form D: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 5.5°±0.2°, 7.2°±0.2°, 15.3°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.9°±0.2°, and 21.1°±0.2°.

[0048] The above crystal forms A, B, C and D can be characterized by X-ray diffraction spectra each having four or more peaks, for example, four, five, six, seven, eight or more, at the 2[θ values ​​presented above.

[0049]

[0050] The organic solvent of the above step (a) may be any organic solvent that can dissolve inabogliflozin and prolyl well, and can form an inabogliflozin / proline co-crystal. An organic solvent that has been verified to be effective in forming an inabogliflozin / proline co-crystal in high yield and also in removing proline used in excess may be at least one organic solvent selected from the group consisting of methanol, ethanol, isopropyl alcohol, 1-butanol, acetone, tetrahydrofuran, acetonitrile, ethyl acetate, dichloromethane, MTBE (Methyl t-Butyl ether), toluene, and dioxane. The organic solvent may be a single solvent or a mixed solvent.

[0051] Preferably, it may be at least one selected from the group consisting of methanol, ethanol, isopropyl alcohol, and acetone. More preferably, the organic solvent may be ethanol.

[0052] Although not limited thereto, the organic solvent of step (a) may be used in a volume of 10 times or more relative to the weight of inavogliflozin, for example, 10 to 200 times relative to the weight of inavogliflozin, for example, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 150, or 200 times relative to the weight of inavogliflozin.

[0053] The amount of organic solvent used may vary depending on the type of organic solvent, or whether it is used as a single solvent or a mixed solvent. For example, in the case of methanol, dioxane, and tetrahydrofuran, cocrystals can be formed with only 10 times the weight of inavogliflozin as a solvent. In the case of ethanol, isopropyl alcohol, 1-butanol, acetone, and acetonitrile, cocrystals were formed even with 50 times the weight of inavogliflozin as a solvent. When ethyl acetate is used as a solvent, the solubility of inavogliflozin is low, so it is necessary to heat at 50 times the weight of inavogliflozin before crystallization. Dichloromethane also has low solubility of inavogliflozin, so a solvent amount of about 100 times the weight of inavogliflozin is required. In the case of MTBE or toluene, the solubility of inavogliflozin in these solvents is very low, so a solvent amount of more than 150 times the weight of inavogliflozin is required.

[0054] Therefore, the type and mixing of organic solvents can be selected and the amount of organic solvent used can be adjusted by considering the solubility of inavogliflozin in the solvent and the degree of co-crystal formation. In addition, heating can be performed concurrently to dissolve inavogliflozin, if necessary.

[0055] In one specific example of the present invention, the organic solvent is ethanol and can be used in a volume of 10 to 60 times the weight of inabogliflozin.

[0056] According to another specific embodiment of the present invention, proline is added in a molar ratio of 1 to 1.5 equivalents with respect to inabogliflozin.

[0057] (b) Stirring of the above result

[0058] Next, the method of the present invention includes a step of stirring the resultant of step (a).

[0059] According to another specific example of the present invention, the stirring in step (b) may be performed at a temperature of 0 to 50°C, for example, 15 to 40°C, preferably 15 to 30°C, more preferably 20 to 25°C.

[0060] According to another specific example of the present invention, the stirring in step (b) may be performed for 0.5 to 24 hours, preferably 1 to 12 hours, and more preferably 4 to 8 hours.

[0061] (c) Vacuum drying of the above result and obtaining inabogliflozin / proline cocrystal

[0062] Finally, the method of the present invention includes a step of vacuum drying the result of step (b) and obtaining an inabogliflozin / proline cocrystal.

[0063] According to another specific example of the present invention, the vacuum drying in step (c) can be performed at a temperature of 30 to 65°C, preferably at a temperature of 40 to 55°C, more preferably at a temperature of 45 to 50°C, for 8 to 12 hours.

[0064] In this way, an inavogliflozin / proline cocrystal can be prepared in which 1 equivalent of inavogliflozin is combined with 1 equivalent of proline, which can be used as a treatment for type 2 diabetes mellitus by inhibiting the reabsorption of blood sugar in the kidney as an SGLT-2 inhibitor and thereby controlling blood sugar by excreting blood sugar in the urine.

[0065] The present invention also provides a pharmaceutical composition comprising the inabogliflozin / proline co-crystal as an active ingredient and a pharmaceutically acceptable carrier.

[0066] The pharmaceutical composition may be, but is not limited to, for the treatment or prevention of diabetes.

[0067] The inabogliflozin / proline co-crystal according to the present invention can be administered in various oral and parenteral dosage forms during clinical administration, and when formulated, it is manufactured using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants.

[0068] The inavogliflozin / proline cocrystal of the present invention increased the solubility of inavogliflozin in artificial gastric fluid and artificial intestinal fluid. This improvement in the solubility of inavogliflozin may be particularly advantageous in the development of oral preparations for indications requiring high-dose administration. The inavogliflozin / proline cocrystal is also very useful as a raw drug substance for inavogliflozin because its stability is the same as that of the existing crystalline form of inavogliflozin. In addition, the inavogliflozin / proline cocrystal of the present invention has a longer half-life and higher in vivo exposure (AUC) than the existing crystalline form A. inf ) and thus the efficacy lasts longer, it can be usefully used in various indications and / or formulation development that require it.

[0069] Figure 1 shows the results of the nuclear magnetic resonance (NMR) H-NMR spectrum of the inabogliflozin / proline cocrystal manufactured according to Manufacturing Example 2.

[0070] Figure 2 shows the results of the nuclear magnetic resonance (NMR) H-NMR spectrum of inabogliflozin crystalline form A manufactured according to Manufacturing Example 1.

[0071] Figure 3 shows the powder X-ray diffraction (PXRD) pattern results of the inabogliflozin / proline cocrystal manufactured according to Manufacturing Example 2.

[0072] Figure 4 shows the powder X-ray diffraction (PXRD) pattern results of inabogliflozin crystalline form A manufactured according to Manufacturing Example 1.

[0073] Figure 5 shows the results of the differential scanning calorimetry (DSC) calorimetric curve of the inabogliflozin / proline cocrystal manufactured according to Manufacturing Example 2.

[0074] Figure 6 shows the results of the differential scanning calorimetry (DSC) calorimetric curve of the inabogliflozin / proline co-crystal, proline, and inabogliflozin crystals manufactured according to an embodiment of the present invention.

[0075] Figure 7 shows a comparison of the solubility of the inabogliflozin / proline cocrystal and the inabogliflozin crystal form manufactured according to the present example in artificial intestinal fluid.

[0076] The advantages and features of the present invention, and the methods for achieving them, will become clearer with reference to the embodiments described in detail below. However, the present invention is not limited to the embodiments disclosed below, but may be implemented in various different forms. These embodiments are provided solely to ensure that the disclosure of the present invention is complete and to fully inform those skilled in the art of the scope of the invention. The present invention is defined solely by the scope of the claims.

[0077]

[0078] [Manufacturing Example 1] Manufacturing of Inabogliflozin Crystalline Form A

[0079] Inabogliflozin crystalline form A, as reported in Experimental Example 4 of Korean Patent Publication No. 2017-0142904, was manufactured.

[0080] Ethyl acetate (15 times the weight of crude inavogliflozin) was added to crude inavogliflozin, dissolved by reflux stirring, and cooled to room temperature. After a suspension was formed at room temperature, the mixture was stirred for an additional 30 minutes. Isopropyl ether (15 times the weight of crude inavogliflozin) was added dropwise to the resulting mixture over 30 minutes, and stirred for an additional 30 minutes at room temperature. The resulting precipitate was filtered, washed with ethyl acetate (2 times the weight of crude inavogliflozin) at 0°C, and dried in a vacuum oven (50°C, 12 hours) to obtain white crystals (yield: 88.3%).

[0081] [Manufacturing Example 2] Manufacturing of Inabogliflozin / Proline Co-Crystal

[0082] 300 mg of inabogliflozin crystalline form A and 10 ml of ethanol were added and stirred at room temperature for 20 minutes. Then, 77.3 mg (1 equivalent) of L-proline was added and stirred at 20-25°C for 1 hour. The precipitated crystals were filtered under reduced pressure, washed with 1 ml of ethanol, and vacuum-dried at 50°C for 12 hours to obtain inabogliflozin / proline co-crystal in crystalline form at a yield of 78%.

[0083] [Manufacturing Example 3] Evaluation of 13 Solvents for L-Proline Co-Crystal Formation

[0084] After dissolving 100 mg (0.224 mmol, 1 equivalent) of inabogliprozin crystalline form A in each solvent, L-proline (0.224 mmol, 1 equivalent) was added at room temperature and stirred for more than 1 hour to evaluate the formation of proline cocrystals.

[0085] SolventSolvent amountCrystal formationMethanol10 mLOEthanol5 mLOIsopropyl alcohol5 mLO1-butanol5 mLOAcetone5 mLOTetrahydrofuran1 mLOAcetonitrile5 mLOEthyl acetate15 mL or moreDichloromethane10 mL or moreOMTBE(Methyl t-Butyl ether)15 mLOToluene15 mLODioxane1 mLODMSO0.1 mLX

[0086] In the case of methanol, dioxane, and tetrahydrofuran, inavogliflozin was completely dissolved even in a solvent amount 10 times the weight of inavogliflozin, and cocrystals were precipitated when L-proline was added. In the case of ethanol, isopropyl alcohol, 1-butanol, acetone, and acetonitrile, cocrystals were formed even in a solvent amount 50 times the weight of inavogliflozin.

[0087] Ethyl acetate and dichloromethane were used as large solvents to dissolve inavogliflozin, and it was confirmed that co-crystals were precipitated when L-proline was added. When ethyl acetate was used as a solvent, it was confirmed that the solubility of inavogliflozin was low, so it was necessary to crystallize after heating at a level of 50 times the weight of inavogliflozin. Dichloromethane also showed low solubility of inavogliflozin, so it was confirmed that a solvent of 100 times the weight of inavogliflozin was required.

[0088] In the case of MTBE or toluene, the solubility of inavogliflozin in these solvents was very low, so more than 150 times the weight of inavogliflozin had to be used, but it was confirmed that cocrystals were slowly formed when L-proline was added.

[0089] On the other hand, in the case of DMSO, it was confirmed that it had high solubility in the co-crystal and did not precipitate.

[0090] Although the amount of solvent needed to be adjusted depending on the solubility according to the polarity of the solvent, proline cocrystals could not be obtained in the case of solvents that affect the solubility of inabogliflozin, L-proline, and cocrystals, such as water and DMSO, but proline cocrystals could be obtained when a certain level of solubility was observed.

[0091] [Experimental Example 1] Nuclear Magnetic Resonance (NMR) Spectrum

[0092] The nuclear magnetic resonance (NMR) H-NMR spectrum was measured for the crystalline form of inavogliflozin obtained according to Manufacturing Example 2. As a result, the nuclear magnetic resonance (NMR) H-NMR spectrum result of the inavogliflozin / proline cocrystal, as shown in Fig. 1, was obtained. Fig. 2 shows the nuclear magnetic resonance (NMR) H-NMR spectrum result of the crystalline form A of inavogliflozin of Manufacturing Example 1. According to Fig. 1, the stoichiometric ratio of inavogliflozin / proline is precisely 1:1, and the peaks are integrated to confirm that the crystalline form of inavogliflozin obtained according to Manufacturing Example 2 is an inavogliflozin / proline cocrystal.

[0093] [Experimental Example 2] Powder X-ray diffraction (PXRD)

[0094] PXRD was measured using Bruker PXRD (30 kV, 10 mA, Cu target) for the inavogliflozin / proline cocrystal obtained according to Manufacturing Example 2. The results in Figure 3 were obtained by performing 5 to 40 ° 2θScan with a 0.02 ° step size. The main peaks are summarized in Table 3 below. The PXRD results according to Figure 3 were clearly distinguished from the PXRD results of inavogliflozin crystalline form A of Manufacturing Example 1 (Figure 4).

[0095] 2θ(±0.2°)d (Å)I / I o (%)2θ(±0.2°)d (Å)I / I o (%)4.7218.733.317.235.150.95.8115.24.918.804.763.26.8113.0100.020.634.316.77.9311.147.021.194.222.58.5910.363.121.754.19.511.118.0 6.822.314.08.912.017.46.024.423.628.313.606.56.225.173.511.714.756.081.626.003.412.315.215.831.027.293.325.416.115.59.027.983.214.5

[0096] [Experimental Example 3] Differential Scanning Calorimetry (DSC)

[0097] Using DSC Q20 obtained from TA, DSC measurements were performed on the inavogliflozin crystalline form A prepared according to Manufacturing Example 1 and the inavogliflozin / proline cocrystal prepared according to Manufacturing Example 2 at a scan rate of 10°C from 30°C to 300°C under nitrogen gas. Figure 5 shows the results of the differential scanning calorimetry (DSC) calorimetry curve of the inavogliflozin / proline cocrystal prepared according to Manufacturing Example 2. The differential scanning calorimetry (DSC) analysis of the inavogliflozin / proline cocrystal confirmed that it exhibited an endothermic peak with an endothermic onset temperature of 217.71°C±3°C and an endothermic temperature of 219.42°C±3°C. Figure 6 shows the results of comparing the calorimetric curves of differential scanning calorimetry (DSC) of inavogliflozin / proline cocrystals, proline, and inavogliflozin crystal forms manufactured according to an embodiment of the present invention. This shows that inavogliflozin crystal form A manufactured according to Manufacturing Example 1 and inavogliflozin / proline cocrystals obtained according to Manufacturing Example 2 clearly show different endothermic onset temperatures and endothermic peaks at different endothermic temperatures.

[0098] [Experimental Example 4] Polymorphism Evaluation of Inabogliflozin / L-Proline Co-Crystal

[0099] 1 mL of the solvent in the table below was added to each 10 mg of inabogliflozin / L-proline cocrystal, and left in a suspended and dissolved state for 24 hours. Then, the formation of polymorphic crystals of inabogliflozin / L-proline cocrystal was evaluated.

[0100] SolventSolvent Polarity (p)DSC (endothermic onset temperature ℃)CrystalPolymorph10.2154.0Crystal Form A VariantAcetonitrile5.8217.0Proline co-crystalEthanol5.2214.1Proline co-crystalMethanol5.1217.3Proline co-crystalAcetone5.1209.7Proline co-crystalEthyl acetate4.4215.1Proline co-crystalTetrahydrofuran4.0212.3Proline co-crystalIsopropyl alcohol3.9215.6Proline co-crystalDichloromethane3.1215.2Proline co-crystalDiethyl ether2.89215.4Proline co-crystalToluene2.4215.8Proline co-crystaln-hexane0.1215.3Proline co-crystal

[0101] As a result of DSC evaluation of the crystals obtained through the experiment, when water was used, a variation of crystal form A was obtained, but when other solvents were used, all were confirmed to be inabogliflozin / L-proline cocrystals with an endothermic onset temperature of approximately 217.71℃±3℃, and no other crystal polymorphs were found.

[0102] [Experimental Example 5] Solubility Evaluation of Inabogliflozin / Proline Co-Crystal

[0103] Since inavogliflozin is poorly soluble with an aqueous solubility of 0.25 mg / ml, a proline cocrystal was prepared to improve the aqueous solubility and gastrointestinal solubility of inavogliflozin. The solubility was measured in artificial gastric fluid and artificial intestinal fluid, which contain many substances that maintain the solubility state, to confirm whether the solubility of the inavogliflozin / proline cocrystal was improved compared to the inavogliflozin crystalline form. The results are summarized in Tables 5 and 6 below, and Fig. 7.

[0104] Solubility in artificial gastric fluid (FaSSGF) Initial 30 minutes 1 hour 2 hours 4 hours Inavogliflozin crystal form A 0.00 mg / mL 0.31 mg / mL 0.34 mg / mL 0.35 mg / mL 0.35 mg / mL Inavogliflozin / proline cocrystal 0.00 mg / mL 0.40 mg / mL 0.41 mg / mL 0.43 mg / mL 0.39 mg / mL

[0105] Solubility in artificial intestinal fluid (FaSSIF)Initial 30 minutes 1 hour 2 hours 4 hoursInavogliflozin crystal form0.00 mg / mL0.69 mg / mL0.94 mg / mL1.00 mg / mL0.92 mg / mLInavogliflozin / proline cocrystal0.00 mg / mL2.02 mg / mL2.20 mg / mL1.98 mg / mL1.04 mg / mL

[0106] As shown in Tables 5 and 6 above, the solubility of the inavogliflozin / proline cocrystal of the present invention in artificial gastric fluid and artificial intestinal fluid increased compared to the inavogliflozin crystalline form, and in particular, as shown in Table 6 and FIG. 7, it was confirmed that the solubility in artificial intestinal fluid increased by about two times or more for up to 2 hours and that the solubility was maintained high for up to 4 hours. Therefore, the inavogliflozin / proline cocrystal of the present invention is a novel solid form that can overcome the low water solubility, which is the problem of the inavogliflozin crystalline form, and it was predicted that the two-fold improvement in the initial solubility in artificial intestinal fluid can significantly improve oral absorption and maximize the efficacy. This improvement in the solubility of inavogliflozin can be particularly advantageous in the development of oral agents for indications requiring high-dose administration.

[0107] [Experimental Example 6] Comparative Evaluation of the Harsh Stability of Inabogliflozin Co-Crystal and Inabogliflozin Crystalline Form

[0108] In order to confirm the possibility of commercializing the inabogliflozin / proline co-crystal of the present invention (Manufacturing Example 2), inabogliflozin crystal form A (Manufacturing Example 1) was used as a control group, and heat stability was tested at 60°C for 4 weeks, and analyzed using liquid chromatography (HPLC) qualitative analysis, and the results are shown in Table 7.

[0109] As shown in Table 7, it was confirmed that the inabogliflozin / proline and inabogliflozin crystal forms were maintained stably without affecting the purity.

[0110] Therefore, it was confirmed that the thermal stability of the inabogliflozin / proline cocrystal was equivalent to that of the inabogliflozin crystal form.

[0111] Results of harsh stability test, 60℃, 4 weeks, initial 2 weeks, 4 weeks, Inabogliflozin / proline co-crystal 99.9%, 99.9%, 99.8%, Inabogliflozin crystal form 99.1%, 98.8%, 99.1%

[0112] [Experimental Example 7] Pharmacokinetic Evaluation of Inabogliflozin / Proline Co-Crystal in Beagles

[0113] This study was conducted to confirm the improvement of the pharmacokinetic profile of inavogliflozin / proline cocrystal in beagle dogs. Inavogliflozin crystalline form A was set as the control group, and proline cocrystal was set as the comparison group. Inavogliflozin crystalline form A and proline cocrystal were orally administered to male beagle dogs at a dose of 1 mg / kg. Blood samples were collected before administration (0 h), 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 h (13 times in total). Blood drug concentrations were analyzed by LC-MS / MS using plasma separated from the collected samples, and pharmacokinetic parameters such as maximum observed plasma concentration (Cmax), area under the plasma concentration-time curve (AUC) were calculated using the WinNonlin 5.0.1 program. last and AUC inf ), time-to-maximum observed plasma concentration (Tmax), half-life (T 1 / 2 ), was calculated and interpreted.

[0114] The results are summarized in Table 8 below.

[0115] Pharmacokinetic evaluation of inavogliflozin / proline cocrystal in beagle dogs Pharmacokinetic parameters Inavogliflozin crystal form A Proline cocrystal Tmax (hr) 4.00 5.20 T 1 / 2 (hr)5.326.10Cmax (ng / mL))482.20482.60AUC last (ng*hr / mL)4340.694428.20AUC inf (ng*hr / mL)4639.385341.58

[0116] As shown in Table 8 above, compared to Inabogliflozin crystalline form A, the proline cocrystal of the present invention has a longer time-to-maximum observed plasma concentration (Tmax) and half-life (T 1 / 2 ) was confirmed slowly, and the PK exposure parameter AUC last  and AUC inf It was confirmed that the proline cocrystal of the present invention has a longer half-life and in vivo exposure (AUC) than the existing crystalline form A. inf ) is high, the proline crystal form is confirmed to be maintained in the body for a little longer and the medicinal effect is expected to last longer. These pharmacodynamic characteristics of the proline co-crystal compared to crystalline form A may have the effect of consuming energy to lower blood sugar as the medicinal effect lasts longer in the body, and activating metabolism in the body due to the secondary effect caused by this. Therefore, these pharmacodynamic characteristics may be useful in the development of various indications and / or formulations.

Claims

An inabogliflozin / proline co-crystal characterized by an X-ray powder diffraction pattern having four or more diffraction peaks at 2[θ] values ​​selected from 4.72±0.2, 6.81±0.2, 7.93±0.2, 8.59±0.2, 14.75±0.2, 15.21±0.2, 17.23±0.2, 18.80±0.2, 21.19±0.2, 24.42±0.2, and 27.29±0.

2.

2. In the first paragraph, the X-ray powder diffraction pattern is characterized by having diffraction peaks at 2[θ] values ​​selected from 6.81±0.2, 8.59±0.2, 14.75±0.2, 17.23±0.2, and 18.80±0.

2.

3. In the first paragraph, a crystalline form characterized by an X-ray powder rotation pattern in which the peak positions are consistent with the peak positions listed in the table below:

4. In the first paragraph, an inabogliflozin / proline co-crystal characterized in that it exhibits an endothermic peak with an endothermic onset temperature of 217.71℃±3℃ and an endothermic temperature of 219.42℃±3℃ in differential scanning calorimetry (DSC) analysis.

5. In the first paragraph, the inabogliflozin / proline cocrystal is an inabogliflozin / proline cocrystal in which 1 equivalent of proline is bound to 1 equivalent of inabogliflozin.

6. A method for producing an inabogliflozin / proline cocrystal according to any one of claims 1 to 5, comprising the steps of: (a) mixing inabogliflozin and an organic solvent and adding proline thereto; (b) stirring the resultant of step (a); and (c) vacuum-drying the resultant of step (b) to obtain an inabogliflozin cocrystal.

7. A method for producing an inabogliflozin / proline co-crystal, wherein the organic solvent is at least one organic solvent selected from the group consisting of methanol, ethanol, isopropyl alcohol, 1-butanol, acetone, tetrahydrofuran, acetonitrile, ethyl acetate, dichloromethane, MTBE (Methyl t-Butyl ether), toluene, and dioxane.

8. A method for producing an inabogliflozin / proline cocrystal, wherein in paragraph 6, the organic solvent is used in a volume 10 to 200 times the weight of inabogliflozin.

9. A method for producing an inabogliflozin / proline co-crystal, wherein the organic solvent is ethanol and is used in a volume 10 to 60 times the weight of inabogliflozin.

10. A pharmaceutical composition comprising an inabogliflozin / proline co-crystal according to any one of claims 1 to 5 as an active ingredient, and a pharmaceutically acceptable carrier.

11. In claim 10, the pharmaceutical composition is a pharmaceutical composition for treating or preventing diabetes.